I note that SRX market cap went up about $300m today (>3 BLTs) on news that their treatment increased life expectancy of sufferers of secondary liver cancer by 7.9 months. Those who don't think that TT-034 efficacy will make a multiple-orders-of-magnitude difference to BLT, please note.